Table 1. Baseline patient characteristics.
| RG-101 (N = 18) | No RG-101 (N = 11) | Total (N = 29) | |
|---|---|---|---|
| Male | 13 (72) | 9 (82) | 22 (76) |
| Weight | 83 (70–98) | 81 (73–91) | 81 (71–93) |
| HCV RNA level | 5.79 | 6.56 | 6.18 |
| (log 10 IU/mL) | (5.16–6.50) | (5.74–6.65) | (5.42–6.59) |
| HCV genotype | |||
| 1a | 9 (50) | 1 (9) | 10 (35) |
| 1b | 1 (6) | 0 | 1 (3) |
| 3 | 7 (39) | 10 (91) | 17 (59) |
| 4 | 1 (6) | 0 | 1 (3) |
| ALT level | 62 (32–85) | 120 (79–151) | 79 (46–123) |
| Fibroscan | 11.0 | 14 (11.9–22.6) | 12.0 |
| result (kPa) | (10.3–13.9) | (10.7–14.8) | |
| Fibrosis stage | |||
| F0-F1 | 2(11) | 0 | 2 (7) |
| F1-F2 | 0 | 0 | 0 |
| F2-F3 | 0 | 0 | 0 |
| F3-F4 | 12 (67) | 7 (64) | 19 (66) |
| F4 | 4(22) | 4 (26) | 8 (28) |
Data are given as median (IQR) or as frequency (percentage). Stage of fibrosis was determined by liver elastography (Fibroscan). Fibrosis score: F0-F1 (–7 kPa), F1-F2 (7–8.8 kPa), F2-F3 (8.9–9.4 kPa), F3-F4 (9.5–14.5 kPa) and F4 (≥14.6 kPa).